VALIDATION OF A PATIENT REPORTED OUTCOME MEASURE (PROM) OF OVARIAN CANCER SYMPTOMS AND TREATMENT RELATED CONCERNS (MOST-OSI) WITH CHEMOTHERAPY IN RECURRENT OVARIAN CANCER (ROC).

被引：0
|
作者：
King, M. [1 ]
Stockler, M. [2 ]
O'Connell, R. [2 ]
Joly, F. [3 ]
Lanceley, A. [4 ]
Hilpert, F. [5 ]
Okamoto, A. [6 ]
Aotani, E. [7 ]
Pignata, S. [8 ]
Donnellan, P. [9 ]
Oza, A. [10 ]
Avall-Lundqvist, E. [11 ]
Berek, J. [12 ]
Buizen, L. [2 ]
Sjoquist, K. [2 ]
Butow, P. [1 ]
Friedlander, M. [13 ]
Gillies, K. [2 ]
Martyn, J. [2 ]
机构：
[1] Univ Sydney, Psychooncol Res Grp, Sydney, NSW 2006, Australia
[2] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[3] Ctr Francoise Baclesse, GINECO, Caen, France
[4] UCL, London, England
[5] Klin Gynakol & Gerburtshilfe, UKSH, Kiel, Germany
[6] Jikei Univ, Sch Med, Tokyo, Japan
[7] Kitisato Acad Res Org, Tokyo, Japan
[8] Natl Canc Inst, Naples, Jamaica
[9] Galway Univ Hosp, Galway, Ireland
[10] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[11] Linkoping Univ, NSGO, Linkoping, Sweden
[12] Stanford Womens Canc Ctr, Stanford, CA USA
[13] Prince Wales Hosp, ANZGOG, GCIG Symptom Benefit StudyGrp GCIG, Kingston, ON, Canada
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-1157
引用
收藏
页码：457 / 458
页数：2
相关论文
共 41 条
  • [1] Validation of the measure of ovarian symptoms and treatment concerns (MOST), a patient-reported outcome measure (PROM) of symptom burden and subjective benefit with chemotherapy in recurrent ovarian cancer (ROC)
    King, Madeleine
    Stockler, Martin
    O'Connell, Rachel
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Pignata, Sandro
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan
    Buizen, Luke
    Sjoquist, Katrin
    Gillies, Kim
    Butow, Phyllis
    Friedlander, Michael
    QUALITY OF LIFE RESEARCH, 2015, 24 : 22 - 23
  • [2] Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
    King, Madeleine T.
    Stockler, Martin R.
    O'Connell, Rachel L.
    Buizen, Luke
    Joly, Florence
    Lanceley, Anne
    Hilpert, Felix
    Okamoto, Aikou
    Aotani, Eriko
    Bryce, Jane
    Donnellan, Paul
    Oza, Amit
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Sehouli, Jalid
    Feeney, Amanda
    Berton-Rigaud, Dominique
    Costa, Daniel S. J.
    Friedlander, Michael L.
    QUALITY OF LIFE RESEARCH, 2018, 27 (01) : 59 - 74
  • [3] Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
    Madeleine T. King
    Martin R. Stockler
    Rachel L. O’Connell
    Luke Buizen
    Florence Joly
    Anne Lanceley
    Felix Hilpert
    Aikou Okamoto
    Eriko Aotani
    Jane Bryce
    Paul Donnellan
    Amit Oza
    Elisabeth Avall-Lundqvist
    Jonathan S. Berek
    Jalid Sehouli
    Amanda Feeney
    Dominique Berton-Rigaud
    Daniel S. J. Costa
    Michael L. Friedlander
    Quality of Life Research, 2018, 27 : 59 - 74
  • [4] A new patient-reported outcome measure for symptom benefit with chemotherapy: the Measure of Ovarian Symptoms and Treatment concerns (MOST)
    King, M. T.
    Stockler, M. R.
    Butow, P.
    O'Connell, R.
    Voysey, M.
    Oza, A. M.
    Gillies, K.
    Donovan, H. S.
    Mercieca-Bebber, R.
    Martyn, J.
    Sjoquist, K.
    Friedlander, M. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 20 - 20
  • [5] Measure of Ovarian Symptoms and Treatment concerns (MOST) indexes and their associations with health-related quality of life in recurrent ovarian cancer
    Campbell, Rachel
    Costa, Daniel S. J.
    Stockler, Martin R.
    Lee, Yeh Chen
    Ledermann, Jonathan A.
    Berton, Dominique
    Sehouli, Jalid
    Roncolato, Felicia T.
    Connell, Rachel O.
    Okamoto, Aikou
    Bryce, Jane
    Oza, Amit M.
    Avall-Lundqvist, Elisabeth
    Berek, Jonathan S.
    Lanceley, Anne
    Joly, Florence
    Hilpert, Felix
    Feeney, Amanda
    Kaminsky, Marie C.
    Diamante, Katrina
    Friedlander, Michael L.
    King, Madeleine T.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (02) : 254 - 262
  • [6] Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)
    Beesley, Vanessa L.
    Ross, Tanya L.
    King, Madeleine T.
    Campbell, Rachel
    Nagle, Christina M.
    Obermair, Andreas
    Grant, Peter
    DeFazio, Anna
    Webb, Penelope M.
    Friedlander, Michael L.
    GYNECOLOGIC ONCOLOGY, 2022, 164 (02) : 437 - 445
  • [7] Development of the Measure of Ovarian Symptoms and Treatment Concerns Aiming for Optimal Measurement of Patient-Reported Symptom Benefit With Chemotherapy for Symptomatic Ovarian Cancer
    King, Madeleine T.
    Stockler, Martin R.
    Butow, Phyllis
    O'Connell, Rachel
    Voysey, Merryn
    Oza, Amit M.
    Gillies, Kim
    Donovan, Heidi S.
    Mercieca-Bebber, Rebecca
    Martyn, Julie
    Sjoquist, Katrin
    Friedlander, Michael L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (05) : 865 - 873
  • [8] PATIENT REPORTED OUTCOME IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER AND METASTATIC BREAST CANCER TREATED WITH METRONOMIC CHEMOTHERAPY
    Krajnak, S.
    Battista, M.
    Almstedt, K.
    Anic, K.
    Heimes, A. S.
    Linz, V.
    Schwab, R.
    Hasenburg, A.
    Schmidt, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A196 - A196
  • [9] WHAT'S THE RELATIONSHIP BETWEEN SYMPTOM CONTROL, PATIENT REPORTED OUTCOME MEASURES (PROM) AND TUMOR MARKERS IN RECURRENT OVARIAN CANCER?
    Hilpert, F.
    ANTICANCER RESEARCH, 2014, 34 (11) : 6821 - 6821
  • [10] Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment
    Campbell, Rachel
    King, Madeleine T.
    Ross, Tanya L.
    Cohen, Paul A.
    Friedlander, Michael L.
    Webb, Penelope M.
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 398 - 407
12345